Shanghai Haohai Biological Technology Co Ltd 2022 AR2
The report highlights Shanghai Haohai Biological Technology's financial and ESG performance for the year 2022. The company achieved a revenue of RMB 2,103.44 million, representing a 20.19% increase compared to 2021, driven by expansion in myopia control and medical aesthetics. On the ESG front, Haohai obtained the ISO 14001 environmental management certification and maintained its ISO 45001 certification. The company also received the 'Shanghai Labor Day Award' and was ranked second in the industry with an ESG rating of AA by Wind.
Company: Shanghai Haohai Biological Technology Co Ltd
Sector: Manufacturing
Country: China
Year: 2022
Type: AR2
Pages: 247
Back to company
Shanghai Haohai Biological Technology Co Ltd
Annual Report
The report highlights Shanghai Haohai Biological Technology's financial and ESG performance for the year 2022. The company achieved a revenue of RMB 2,103.44 million, representing a 20.19% increase compared to 2021, driven by expansion in myopia control and medical aesthetics. On the ESG front, Haohai obtained the ISO 14001 environmental management certification and maintained its ISO 45001 certification. The company also received the 'Shanghai Labor Day Award' and was ranked second in the industry with an ESG rating of AA by Wind.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Workplace Fatalities
Employees